Login to Your Account



Clinic Roundup


Tuesday, October 8, 2013
• Cardiome Pharma Corp., of Vancouver, British Columbia, said data from an observational, retrospective study including 251 recent-onset atrial fibrillation (AF) patients receiving Brinavess (vernakalant) treatments during the period between Jan. 15, 2011, and April 15, 2013, showed that 70 percent converted with a median time of 11 minutes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription